Tramadol Use and Risks

Introduction to Tramadol Risks

The Centers for Disease Control and Prevention recommends that tramadol should generally be avoided for long-term pain management due to lack of evidence for sustained efficacy beyond 1 year, significant risks of addiction, overdose, and mortality, and the availability of safer alternatives 1

No randomized controlled trials exist evaluating tramadol for chronic pain beyond 1 year, and no studies have demonstrated long-term benefits for pain, function, or quality of life 1
One cohort study found long-term opioid therapy (including tramadol) was not associated with improved pain, function, or other outcomes versus no opioids 1
The European Society for Medical Oncology notes that the effectiveness of tramadol as a "step 2" weak opioid has a time limit of 30-40 days for most patients, with progression to stronger opioids typically required due to insufficient analgesia rather than adverse effects 2

Long-term tramadol use is associated with increased risks of addiction (8-12%), overdose, fractures, falls, cardiovascular events, and all-cause mortality 1
Higher dosages correlate with increased risks of overdose, addiction, endocrinological adverse events, and incident or refractory depression 1

Tramadol inhibits serotonin and norepinephrine reuptake in addition to its weak opioid effects, creating substantial risk when combined with other serotonergic medications 3
The American College of Physicians recommends avoiding or using extreme caution with SSRIs, SNRIs, TCAs, and MAO inhibitors due to potentially fatal serotonin syndrome 4

The maximum daily dose is 400 mg for immediate-release or 300 mg for extended-release formulations in adults with normal hepatic and renal function, according to the National Institute for Health and Care Excellence 3
Tramadol exhibits a "ceiling effect" where doses above the threshold do not increase effectiveness but only increase side effects 2

Tramadol is positioned as a second-line agent for neuropathic pain, reserved for patients who have not responded to first-line medications (gabapentinoids, SNRIs, TCAs), as recommended by the American Academy of Neurology 4
The American Diabetes Association notes that for diabetic peripheral neuropathy, tramadol can be effective but is not recommended for long-term use given the lack of long-term efficacy data and documented harms 5
For neuropathic pain: gabapentinoids (pregabalin, gabapentin), SNRIs (duloxetine, venlafaxine), or TCAs are first-line with better long-term safety profiles, according to the European Federation of Neurological Societies 4

Do not prescribe tramadol long-term without attempting first-line non-opioid alternatives, as recommended by the Centers for Disease Control and Prevention 1
Do not combine tramadol with SSRIs, SNRIs, TCAs, or MAOIs without careful consideration of serotonin syndrome risk, according to the American College of Physicians 3
Do not exceed maximum daily doses (400 mg IR, 300 mg ER) or adjust for renal/hepatic impairment and elderly patients, as recommended by the National Institute for Health and Care Excellence 3
Do not prescribe tramadol as a "safer" long-term opioid alternative—the evidence does not support this assumption, according to the Centers for Disease Control and Prevention 1

Evaluate pain, function, and quality of life regularly; discontinue if no meaningful benefit, as recommended by the Centers for Disease Control and Prevention 1
Monitor for adverse effects including constipation, nausea, sedation, dizziness, and cognitive impairment, according to the European Society for Medical Oncology 3